SMC advice on the use of bortezomib for previously untreated myeloma patients who are eligible for high-dose chemotherapy and stem cell transplantation

SMC advice for the restricted use of bortezomib in combination with dexamethasone and thalidomide as induction treatment for previously untreated myeloma patients who are transplant eligible.